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Abstract
Background: Early onset lung cancer shows some familial aggregation, pointing to a genetic
predisposition. This study was set up to investigate the role of candidate genes in the susceptibility
to lung cancer patients younger than 51 years at diagnosis.
Methods: 246 patients with a primary, histologically or cytologically confirmed neoplasm,
recruited from 2000 to 2003 in major lung clinics across Germany, were matched to 223 unrelated
healthy controls. 11 single nucleotide polymorphisms of genes with reported associations to lung
cancer have been genotyped.
Published: 25 February 2008
BMC Cancer 2008, 8:60 doi:10.1186/1471-2407-8-60
Received: 3 August 2007
Accepted: 25 February 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/60
© 2008 Rosenberger et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
BMC Cancer 2008, 8:60 http://www.biomedcentral.com/1471-2407/8/60Results: Genetic associations or gene-smoking interactions was found for GPX1(Pro200Leu) and
EPHX1(His113Tyr). Carriers of the Leu-allele of GPX1(Pro200Leu) showed a significant risk
reduction of OR = 0.6 (95% CI: 0.4–0.8, p = 0.002) in general and of OR = 0.3 (95% CI:0.1–0.8, p
= 0.012) within heavy smokers. We could also find a risk decreasing genetic effect for His-carriers
of EPHX1(His113Tyr) for moderate smokers (OR = 0.2, 95% CI:0.1–0.7, p = 0.012). Considered
both variants together, a monotone decrease of the OR was found for smokers (OR of 0.20; 95%
CI: 0.07–0.60) for each protective allele.
Conclusion: Smoking is the most important risk factor for young lung cancer patients. However,
this study provides some support for the T-Allel of GPX1(Pro200Leu) and the C-Allele of
EPHX1(His113Tyr) to play a protective role in early onset lung cancer susceptibility.
Background
Lung cancer is the most common cause of death from can-
cer in the world. The estimated total number of cases is 1.2
million annually and is still increasing [1,2]. For men lung
cancer mortality is declining in Germany since nearly a
decade, whereas the incidence in women is increasing.
However for men and women of age 50 or younger the
incidence of lung cancer is low [1].
The major cause of lung cancer is tobacco smoke, prima-
rily of cigarettes, increasing the risk 15- to 30-fold. 90% of
lung cancer cases can be attributed to a life long inhala-
tion of tobacco smoke [1,3]. Additionally occupational
(e.g. asbestos at workplace), environmental (e.g. passive
smoking or ambient air pollution) and behavioral risk
factors (e.g. diet) have been identified [1,2,4-14].
The median age of onset is 66 years; about 5% to 10% of
patients are younger than 50 years. These young patients
differ from older patients regarding the distribution of sex,
histological type of the neoplasm and in genetic suscepti-
bility [15-24]. Smoking remains to be the major risk factor
in these younger patients [25-27], but familial aggregation
of lung cancer was identified as a consistent additional
risk factor in several epidemiological studies [28-37].
Recent investigations from Germany showed a 2.6-fold
increased lung cancer risk in young patients (OR, 95% CI
1.6–6.0) if first degree relatives had cancer[27] and a 4.7-
fold increased risk if a parent or sibling was affected with
lung cancer [38]. Even for nonsmokers in the age between
40 and 59 an increase of the lung cancer risk up to 6-fold
was seen in the presence of lung cancer in a first-degree
relative [39].
The results of a segregation analysis suggest the presence
of a high risk gene contributing to early-onset of lung can-
cer particularly in nonsmokers [40]. Another indication
for a genetic contribution to lung cancer in the young is
given by a larger increase of risk in monozygotic com-
pared to dizygotic young twins, which was more evident
in female than in male twins [41]. No such risk differences
could be seen in a cohort of twins older than 50 [42].
Hence, the etiology of lung cancer in patients before age
50 seems to differ from that in older patients by a stronger
genetic component, likely to interact with the exposure to
tobacco smoke.
While smoking the body absorbs numerous carcinogens
that need to be eliminated. In recent years several cytoge-
netic and molecular biological studies indicated chromo-
somal regions or candidate genes as linked to or
associated with lung cancer. For example, a major suscep-
tibility gene locus in the region of 6p23-25 was found to
be linked in families with three or more individuals
affected by lung, throat, or laryngeal cancer [43]. It can be
hypothesized that gene products regulating phase I and II
enzymes [15,44,45], tumor suppressor genes [46] and
DNA repair genes [47-49] are associated with the develop-
ment of lung cancer, but results are contradictory.
This study was set up to further clarify associations of
DNA variants in candidate genes for metabolizing
enzymes, a tumor suppressor gene and genes relevant for
DNA repair and their interaction with smoking in lung
cancer patients with age of onset 50 years or younger.
Methods
Study Design and Study Subjects
We carried out a frequency matched case-control study.
Caucasian patients with newly diagnosed and histologi-
cally or cytologically confirmed primary lung cancer with
age 50 years or younger were recruited in 21 major lung
clinics across Germany. They completed an interviewer-
administered questionnaire in which detailed informa-
tion on personal history, history of lung diseases, family
history of cancer and smoking habits were assessed. Blood
samples were taken from all patients. A DNA bank was
established. From July 2000 to April 2003 blood samples
and case report forms were obtained from 247 young lung
cancer patients. One of the patients was excluded because
the parents were Vietnamese.Page 2 of 12
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BMC Cancer 2008, 8:60 http://www.biomedcentral.com/1471-2407/8/60Cancer free control individuals are a random sample (fre-
quency matched by 5-year age categories and sex to cases)
drawn from the participants of a population based survey
(KORA – Cooperative Health Research in the Region of
Augsburg [50], survey S4). KORA, a continuation of the
WHO MONICA study, provides a platform for research in
epidemiology, health economics and genetics, where data
and blood samples can made available. Since 1984/85
four representative surveys have been performed, includ-
ing approximately 4000 – 5000 adults each.
After excluding one control individual because the prepa-
ration of the blood sample for genotyping failed, a total of
246 cases were subsequently compared with 223 control
individuals. With respect to yet genotyped markers nei-
ther major population stratification between the whole
KORA sample (southwest Germany) or two other cohorts
from Northern Germany [51] nor deviations in the Minor
Allele Frequencies (MAFs) to those of the HapMap Ceu
Population could be detected.
The study was approved by the ethics committee of the
Bayerische Landesärztekammer München and all neces-
sary local ethic committees of the involved recruitment
clinics. All participants signed an informed consent form.
Selection of candidate genes and single nucleotide 
polymorphism (SNP)
The selection of DNA variants in candidate genes for this
study was based on two criteria: published significant
association together with plausible biological relevance of
a polymorphism to lung cancer. We searched MEDLINE
for reviews about the genetics of lung cancer published
between 1995 and 2002. (Search term: "Lung Neoplasms/
genetics" [Mesh] AND ("molecular" [TI] OR "gene" [TI]
OR "genetic" [TI]) Limits: Publication Date from 1995/1/
1 to 2003/1/1, Humans, Review, English, German). From
138 hits, we selected 35 by screening for promising titles
or abstracts. All mentioned genes and DNA variants with
significant association in these reviews and in a wide rang-
ing selection of original study reports were listed. Two
experts in the molecular biology of cancer rated these
DNA variants for plausible biological relevance to lung
cancer. The final selection furthermore also needed to
meet limited financial constraints.
We investigated the following 11 SNPs:
CYP1A1(Val462Ile) (Cytochrom-P450 Enzyme, rs10489
43), EPHX1(His113Tyr) and EPHX1(Arg139His) (micro-
somal Expoide Hydrolase, rs1051740, rs2234922),
GSTP1(A-193C) (Glutathione S-Transferase, rs947895),
NAT2(Thr114Ile) and NAT2(Gln197Arg) (N-Acetyl-Trans-
ferase 2, rs1801280, rs1799930), GPX1(Pro200Leu) (Glu-
tathione Peroxidase 1, rs1050450), p53(Arg72Pro) (tumor
suppressor gene, rs1042522), XRCC1(Arg280His) and
XRCC1(Arg399Gln) (X-ray Repair Cross-Complementing
group1, rs25489, rs25487) and finally XPD(Asp312Asn)
(Xeroderma Pigmentosum group D, rs1799793).
Blood Sampling and Genotyping
Blood samples (4 × 9 ml) were taken by clinicians and
sent to the study center (GSF-National Research Centre for
Environment and Health) within 24 hours. Immortalized
cell lines were prepared and stored in liquid nitrogen.
DNA was isolated from fresh or frozen blood using the
DNA isolation kit of Gentra, Minneapolis, and stored at -
80°C. Genotyping of SNPs was performed by matrix-
assisted laser desorption/ionization time-of flight
(MALDI-TOF MS, Sequenom) according to Weidinger et
al. [50]. Standard genotyping quality control including
10% duplicate samples, checking for Hardy-Weinberg
equilibrium as well as negative samples revealed no major
errors. In none of the duplicate samples a deviating geno-
type could be determined.
Statistical Methods
When investigating potential modifications for lung can-
cer risk by marker genotypes, we considered sex, age and
smoking habits as covariates. Patient's age was defined by
age at first diagnosis, while for KORAS4 controls age at
recruitment was recorded. Cumulative smoking exposure
of former and current smokers was measured as packyears
(PY). Cases and controls were grouped according to their
smoking exposure level (SEL) into never and light smok-
ers (≤1 PY), moderate (1-<20 PY) and heavy smokers (20
and more PY).
For cases we collected the smoking history in detail, as rec-
ommended [52]. For controls PY had to be approximated
from the last amount of cigarette consumption per day
and the duration of smoking. Preliminarily we classified
all cases into the upper mentioned grouped by both con-
cepts. We found these classifications to agree for 79% of
cases. A similar agreement had been found by Bernaards
et al. [53], when comparing retrospectively calculated PY
with prospectively calculated PY. They concluded, that
misclassification error in categorizing PY is smaller than
quantitative error on continuous retrospectively PY calcu-
lation. Hence, we assume the use of PY groups to be at
least as reliable as the collected retrospectively PY.
Using exact tests the distribution of histological subtypes
was compared to a published German collection of 251
lung cancer patients with age of onset before the age of 46
years [20].
Hardy Weinberg equilibrium (HWE) was tested in con-
trols using a likelihood ratio test [54].Page 3 of 12
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BMC Cancer 2008, 8:60 http://www.biomedcentral.com/1471-2407/8/60As exact tests of genetic association we performed a BWS-
Test (Baumgartner-Weiss-Schindler-Test [55]). These tests
were also carried out in subsamples according to sex, age
(grouped in age of onset ≤ 45 years and age of onset = 46–
50 years, which almost splits the sample in two equally
sized groups), smoking status (never, former and current
smoker) as well as SEL (never and light, moderate, heavy
smokers) and histological tumor subtype (small-cell, SCC
and adenocarcinoma). For markers showing any signifi-
cant association we performed two logistic regression
models including age and sex as covariables. In model I
smoking exposure level (SEL) was incorporated as the
main effect while the genotype was nested within the SEL
groups. Thus the genetic association was investigated
nested within the SEL groups. The relative chance for lung
cancer is estimated compared to genetic protected of the
same smoking exposure. We also test for modification of
the genetic effect by smoking by testing the contrast
between the estimated parameters of model I for never or
light smokers versus for moderate or heavy smokers.
In model II SEL-genotype interaction was directly
included. Here all effects are given in comparison to
wildtype-never and lightsmokers. The relative chance for
lung cancer is estimated compared to genetic protected
never or light smokers. Similar models were fitted with
smoking status instead of SEL.
When appropriate, only subgroups of patients of a partic-
ular histological subtype were included. Motivated by sin-
gle marker results on two genes we defined a genetic
protection score (gPS) as the count of protective alleles,
which are the T-allele of GPX1(Pro200Leu) and the C-
allele of EPHX1(His113Tyr). Logistic regression including
gPS was performed as described above.
We also carried out a sensitivity analysis for missing data.
The level of significance was set to 5% for all tests. To take
multiple comparisons into account, the p-values of BWS
tests were interpreted at the familywise significance level
of 5%/11 = 0.445%.
Results
Most patients were men (75%). The median age at diag-
nosis was 46 years for both sexes, which ranges from 24 to
50 years. For about 80% of the cases both parents were
originating from Germany, further 8% had at least one
German parent. Almost all non-German parents came
from other European countries or North-America. Table 1
shows the characteristics of patients and controls.
Histological subtypes of lung cancer
As expected, the leading histological subtypes were squa-
mous-cell carcinoma (SCC) in men (30%) and adenom-
acarcinoma in women (37%). The gender specific
distributions of histological subtypes within cases were
similar to an other German study [20]. For more details
see Table 1.
Smoking habits
Nearly all patients (97% of men, 87% of women) were
ever smokers (current or former) with high tobacco con-
sumption (current smokers: mean 32.4 PY, former smok-
ers: mean 28.8 PY). According to the cumulative smoking
Table 1: Sex, age smoking (in pack years) and histological subtypes of lung cancer in the study samples
Cases Controls
Sample size 246 223
Sex (m/f) 185/61 (~3:1) 167/56 (~3:1)
Male Female Male Female
Age (mean +/- sd) 45.5 ± 4.1 44.9 ± 4.9 44.8 ± 3.9 44.9 ± 3.3
24–40 years 21 (11%) 7 (11%) 19 (11%) 6 (11%)
41–45 years 57 (31%) 18 (30%) 61 (37%) 24 (43%)
46–50 years 107 (58%) 36 (59%) 87 (52%) 26 (46%)
Smoking
Packyears (mean +/- sd)* 32.3 ± 17.5 26.2 ± 12.4 27.1 ± 13.3 14.6 ± 10.2
never and light smoker (≤1 PY) 7 (4%) 8 (14%) 66 (65%) 32 (73%)
moderate smoker (1-<20 PY) 40 (23%) 14 (24%) 12 (12%) 9 (20%)
heavy smoker (20-PY) 130 (73%) 37 (63%) 23 (23%) 3 (7%)
former smoker 4 -- 66 12
Histological subtype
Small-cell (SCLC) 45 (24%) 20 (33%)
Adenocarcinoma 54 (29%) 23 (37%)
Squamous-cell carcinoma (SCC) 55 (30%) 9 (15%)
Others 31 (17%) 9 (15%)
Total 185 61
* for controls packyears (py) have been calculated from the current amount of cigarette consumption per day and the duration of smokingPage 4 of 12
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BMC Cancer 2008, 8:60 http://www.biomedcentral.com/1471-2407/8/60dose 2 of 3 patients (men: 73%, women: 63%) were clas-
sified as highly exposed to tobacco (≥20 pack years), while
in controls this were 14% and 5%, respectively. Further-
more, the frequency of 55% female smokers among
patients clearly exceeded the nationwide percentage given
by the micro-census 1998 (31% at 15 to 50 years of age)
[56].
Genotypes
The call rates of genotyping were on average 91% across
markers.
Estimated allele frequencies are given in Table 2. Signifi-
cant departures from HWE were not found in controls and
only for p53 (Arg72Pro) in patients (p = 0.0384). Results
of BWS-tests for a genetic association, an estimator of a
main genetic effect within the total study population, age
groups, male and female and current smokers are given in
Table 3.
Genetic association analysis
The estimated odds ratios for lung cancer were OR = 6.6
(95% CI: 3.4–12.8) for moderate and OR = 22.7 (95% CI:
11.9–43.3) for heavy smokers without taking any genetic
marker information into account.
GPX1(Pro200Leu)
Among the 11 markers investigated, only the marker for
the GPX1(Pro200Leu) gene showed a significant differ-
ence in the distribution of genotypes between all cases
and controls (pBWS-Test = 0.002). The variant T-allele was
associated with a lower risk for lung cancer and showed a
frequency of 22% (95% CI: 20%–24%) in cases, com-
pared to 31% (95% CI: 29%–33%) in controls. Signifi-
cant association could also be observed within men (pBWS-
Test = 0.011) and women (pBWS-Test = 0.020), current (pBWS-
Test = 0.034), former smokers (pBWS-Test = 0.001) and heavy
smokers (pBWS-Test = 0.003), in patients younger than 46
years of age (pBWS-Test = 0.004), in patients with adenocar-
cinoma (pBWS-Test = 0.024) and in patients with SCC (pBWS-
Test = 0.007).
Carriers of the T-allele showed a risk reduction of OR = 0.3
(95% CI:0.1–0.8, p = 0.012) within heavy smokers
whereas for moderate smokers (OR = 0.6, 95% CI:0.2–
1.6, p = 0.278) and for never and light smokers (OR = 0.9,
95% CI:0.3–3.0, p = 0.825) significance was not reached.
Because of the small number of never or light smokers
beyond cases no significance (p = 0.9012) was achieved
when testing for modification or the genetic effect by SEL
groups. Even if the T-allele seems to have some protective
Table 2: SNP allele frequencies compared with frequencies from literature
Marker Minor Allele Group* Call rate Genotype Frequency [%]§ Allele Frequency [%]
n 0 1 2 95% CI pub.**
CYP1A1(VAL462ILE) G P 91% 217 93 7 0 3 3–4 2 [57]
C 212 92 8 0 4 3–4
GSTP1(A-193C) G P 94% 221 43 45 12 34 32–36 30 [58]
C 218 43 49 8 32 30–34
EPHX1(His113Tyr) C P 96% 233 55 38 7 26 25–28 32 [57]
C 219 49 43 8 29 28–31
EPHX1(Arg139His) G P 86% 191 68 29 4 18 17–20 22 [57]
C 208 69 27 3 17 16–18
NAT2(Thr114Ile) C P 94% 222 34 51 15 41 39–43 46 [57]
C 218 31 55 14 42 39–44
NAT2(Gln197Arg) A P 95% 229 50 44 7 28 27–30 29 [57]
C 218 50 41 10 30 28–32
XPD(Asp312Asn) A P 92% 221 39 45 15 38 36–40 33 [49]
C 209 37 45 18 40 38–42
XRCC1(Arg280His) A P 94% 232 91 9 1 5 5–6 3 [59]
C 211 90 10 0 5 5–6
XRCC1(Arg399Gln) A P 86% 197 43 44 13 35 33–38 38 [59]
C 204 43 45 12 34 32–37
GPX1(Pro200Leu) T P 85% 186 61 34 5 22 20–24 31 [60]
C 207 47 43 10 31 29–33
p53(Arg72Pro)§§ C P 87% 201 56 34 10 27 25–29 33 [61]
C 204 56 38 6 25 23–27
* P: patients, C: controls
** published allele frequency within Caucasian populations [reference]
§ 0. homozygous wildtype allele, 1. heterozygous, 2. homozygous for predisposing allele
§§ Only the distribution of genotypes of p53(Arg72Pro) in cases (P) differed significantly from HWE (p = 0.0384, likelihood ratio test)Page 5 of 12
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BMC Cancer 2008, 8:60 http://www.biomedcentral.com/1471-2407/8/60effect, the risk for lung cancer for moderate and heavy
smokers in the presence of a T-allele is clearly increased
compared to 'genetically unprotected' never and light
smokers (moderate: OR = 10.1, heavy: OR = 22.1). For
more details see Table 4.
EPHX1(His113Tyr)
The SNP within exon 3 of the EPHX1 gene showed signif-
icant associations within current smokers (pBWS-Test =
0.015). Within current smokers the variant C-allele was
associated with a lower risk for lung cancer and showed a
Table 3: p-values for Baumgartner-Weiss-Schindler test for genetic association and OR for main genetic effects
Marker Sex Current smoker
Total study pop. Women Men
p-value OR** 95%-CI p-values
CYP1A1(Val462Ile) rs1048943 0.857 0.68 0.30–1.51 1.000 0.838 0.833
GSTP1(A-193C) rs947895 0.213 0.96 0.62–1.48 0.396 0.138 0.166
EPHX1(His113Tyr) rs1051740 0.175 0.67 0.44–1.03 0.178 0.419 0.015
EPHX1(Arg139His) rs2234922 0.366 1.41 0.86–2.30 0.243 0.475 0.342
NAT2(Thr114Ile) rs1801280 0.445 1.01 0.64–1.59 0.450 0.355 0.131
NAT2(Gln197Arg) rs1799930 0.252 1.02 0.66–1.55 0.241 0.445 0.291
XPD(Asp312Asn) rs1799793 0.262 0.96 0.61–1.50 0.437 0.155 0.388
XRCC1(Arg280His) rs25489 0.417 0.76 0.38–1.50 0.354 0.793 0.624
XRCC1(Arg399Gln) rs25487 0.385 0.82 0.52–1.29 0.409 0.409 0.453
GPX1(Pro200Leu) rs1050450 0.002* 0.50 0.32–0.79 0.020 0.011 0.034
p53(Arg72Pro) rs1042522 0.190 1.14 0.72–1.80 0.127 0.385 0.278
p-values < 0.05 are bold.
* p-values below Bonferroni-corrected significance level of α' = 0.05/11 = 0.0045
** OR: Odds ratios adjusted for smoking exposure level (SEL), age and sex
Table 4: Genetic association estimates and smoking for GPX1(Pro200Leu) and EPHX1(His113Tyr)
Relative chance for LC compared to ...
Genetic protected never or light 
smokers *




Genetic disposition n cases:controls OR 95% CI OR 95% CI
GPX1(Pro200Leu)
Never and light 
smoker
CC 11:53 1.0 Reference 1.0 Reference
T-carrier 5:42 0.9 0.3 – 3.0 0.9 0.3 – 3.0
Moderate smoker CC 30:9 18.4 6.1 – 55.8 1.0 Reference
T-carrier 15:12 10.1 3.4 – 30.2 0.6 0.2 – 1.6
Heavy smoker CC 86:9 70.1 24.5 – 200 1.0 Reference
T-carrier 52:16 22.1 8.3 – 59.3 0.3 0.1 – 0.8
EPHX1(His113Tyr)
Never and light 
smoker
TT 1:10 1.0 Reference 1.0 Reference
C-carrier 18:88 1.4 0.5 – 4.1 1.4 0.5 – 4.1
Moderate smoker TT 4:2 40.0 12.2 – 131 1.0 Reference
C-carrier 58:19 11.1 4.0 – 31.2 0.2 0.1 – 0.7
Heavy smoker TT 14:2 58.2 20.9 – 161 1.0 Reference
C-carrier 153:23 45.5 16.6 – 124 0.8 0.3 – 1.9
* odds ratio. adjusted for sex and age
§ odds ratio of allele carriers compared to non carriers within the same smoking group
SEL smoking exposure level: never and light smokers: ≤1 pack years. moderate smokers: 1-<20 pack years. heavysmokers: ≥20 pack years.Page 6 of 12
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BMC Cancer 2008, 8:60 http://www.biomedcentral.com/1471-2407/8/60frequency of 25% (95% CI: 21%–28%) for cases, com-
pared to 36% (95% CI: 32%–40%) for controls.
We could find a risk decreasing genetic effect for C-carriers
only for moderate smokers (OR = 0.2, 95% CI:0.1–0.7, p
= 0.012). Please note the small number of TT-carriers
within cases and controls, which lowers the evidence –
not the significance – of this finding. No such significant
effect was found for heavy smokers (OR = 0.8, 95%
CI:0.3–1.9, p = 0.593), where the 95%-confidence inter-
val for OR does not cover the point estimate of OR for
moderate smokers. For more details see Table 4. Because
of the small number of never or light smokers beyond
cases no significance (p = 0.1898) was achieved when test-
ing for modification or the genetic effect by SEL groups.
GPX1(Pro200Leu) and EPHX1(His113Tyr)
As a combined effect of these two polymorphisms, one
might look at the count of protective alleles (T for
GPX1(Pro200Leu), C for EPHX1(His113Tyr)) as a genetic
prediction score (gPS). Such a score – modeled as contin-
uous variables – yields an estimated OR per predisposing
allele of 1.03 (95% CI: 0.5–2.0, p = 0.943) for never and
light smokers, OR = 0.48 (95% CI: 0.2–1.1, p = 0.067) for
moderate and OR = 0.55 (95% CI: 0.3–0.9, p = 0.020) for
heavy smokers (over all SEL levels: p = 0.033). The differ-
ence between moderate and heavy smokers was not found
significant (p = 0.777). Because of the small number of
never or light smokers beyond cases no significance (p =
0.1770) was achieved when testing for modification or
the effect of gPS by SEL groups.
In the presence of one protective allele only (gPS = 1) no
differences in the decrease of lung cancer risk compared to
gPS = 0 could be found between moderate (OR = 0.5, 95%
CI:0.1–3.0), heavy (OR = 0.4, 95%: 0.1–1.3) and never
and light smokers (OR = 0.4, 95% CI:0.1–2.0) (see Figure
1 and Table 5). In the presence of two or more protective
alleles (gPS > 1) the risk for lung cancer further decreases
for moderate and heavy smokers (OR = 0.2, 95% CI:0.1–
0.6). For never and light smokers no further risk reduction
was observed. However, the subsample of never and light
smokers is too small to gain statistical evidence for such a
conclusion (only 2 never and light smoking cases have a
gPS > 2).
Please note, even if both DNA-variants independently
showed some protective effect for smoking exposed indi-
viduals, the risk for lung cancer in the double protected
ever smokers (gPS ≥ 3) was significantly higher (OR = 4.8,
95% CI: 1.8–20, p = 0.028) compared to genetically
unprotected never and light smokers (gPS = 0).
NAT2(Gln197Arg)
For the marker NAT2(Gln197Arg) we did not find an
overall association (pBWS = 0.252, crude ORper A-allele = 1.0,
Change of the protective genetic association for lung cancer with gPSFigur 1
Change of the protective genetic association for lung cancer with gPS. gPS: genetic Protection Score:count of pro-
tective alleles of GPX1(Pro200Leu) and of EPHX1(His113Tyr). Odds ratio estimates, significant at p < 0.1, are highlighted with 
filled symbols.











0 1 2 3 or 4
gPS (count of protective alleles) 
all smokers
never smokers (<1 PY)
moderate smokers (1-20 PY)
severe smokers (20- PY)Page 7 of 12
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BWS-test yielded p-values between 0.163 and 0.495. The
only exception were patients with adenocarcinoma (pBWS
= 0.014).
GSTP1(A-193C)
For GSTP1(A-193C) we did not find an overall genetic
association (pBWS = 0.213, crude ORper G-allele = 1.1, 95%
CI: 0.8–1.4). In the investigated subgroups the BWS-test
yielded p-values between 0.101 and 0.490, with two
exceptions. For patients with SCC we achieved a pBWS =
0.01. For heavy smokers significance was slightly missed
(pBWS-Test = 0.089).
For none of the other markers any significant genetic asso-
ciation was observed.
Discussion
Some chromosomal regions or candidate genes are indi-
cated as associated with lung cancer of any age of onset,
additionally and/or interactively to the main risk factor
tobacco smoking by several studies yet. For lung cancer
with age of onset before age 50 a consistent familial aggre-
gation was observed. The main interest of this study was
to investigate the role of some candidate markers for early-
onset lung cancer patients.
GPX1(Pro200Leu)
Antioxidant enzymes like glutathione peroxidase (GPX)
are thought to be the primary cellular defence mechanism
against reactive oxygen species. The lung epithelium is in
particular endangered by exogenous NOx that causes
epoxides, aldehydes and peroxides. They react to superox-
idradical anion and hydrogen peroxide and in the pres-
ence of transition metal ions these continue to react to the
aggressive OH radical. These reactive oxygen species
(ROS) have the ability to cause massive injury to the cell.
They are involved in inflammation processes, peroxida-
tion of membranes which influences their permeability,
binding on SH-groups of several enzymes which interferes
its activity. Extracellular and intracellular antioxidative
defence systems protect the cells from this damage. Extra-
cellular defence is mainly done by small molecular parti-
cles like vitamins and small molecular proteins.
Intracellular antioxidative defence mostly consists of the
anti oxidative enzymes from the glutathion redox cycle
(glutathion reductase and glutathion peroxidase). GPX is
a tetramerical enzyme with four selenium-atoms bound
as selenocystein in the active centre. It is important in the
cellular defence against cytotoxic lipid peroxidation prod-
ucts [62]. The catalytic activity of GPX depends on the
availability of reduced glutathione as coenzyme and on
several endogenous and exogenous influences like geno-
type and nutrition. Smokers need more protection against
Table 5: Genetic association estimates for GPX1(Pro200Leu) and EPHX1(His113Tyr) accounting for smoking
Relative chance for LC compared to ...
Genetic protected never or light 
smokers




gPS*: count of 
protective alleles
n cases:controls OR 95% CI OR 95% CI
Never and light 
smoker
0 8:28 1.00 Reference 1.00 Reference
1 4:39 0.43 0.09 – 1.93 0.43 0.09 – 1.93
2 2:22 0.50 0.09 – 2.85 0.50 0.09 – 2.85
3 or 4 2:6 1.91 0.29 – 12.4 1.91 0.29 – 12.4
Moderate smokers 0 15:2 24.7 4.05 – 150 1.00 Reference
1 20:8 12.8 3.60 – 45.4 0.51 0.09 – 2.95
2 9:11 4.1 1.07 – 15.4 0.17 0.03 0.99
3 or 4 1:0 -- --
Heavy smokers 0 40:3 74.4 16.2 – 341 1.00 Reference
1 57:12 25.7 8.14 – 81.5 0.35 0.09 – 1.31
2 26:7 18.9 5.15 – 69.2 0.25 0.06 – 1.08
3 or 4 6:3 10.2 1.78 – 58.2 0.14 0.02 – 0.87
All smokers 0 1.00 Reference
1 0.40 0.14 – 1.15
2.3.4 0.20 0.07 – 0.60
* no. protective alleles of GPX1(Pro200Leu) and EPHX1(His113Tyr)
** odds ratio. adjusted for sex and age
§ odds ratio of allele-carriers compared to non-carriers within the same smoking group
SEL smoking exposure level: never and light smokers: ≤1 pack years. moderate smokers: 1-<20 pack years. heavysmokers: ≥20 pack yearsPage 8 of 12
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cer protecting role of vitamins C and E. However drinking
alcohol is also found to increase the daily demand for
vitamins [63,64].
Ratnasinghe et al. [65] found evidence for association
with lung cancer for a Pro→Leu (C→T) polymorphism at
the amino acid position 200 of the GPX1-gene in a sample
of Caucasian men aged 50–69 years which currently
smoked at least five cigarettes per day. The odds ratio for
heterozygotes (CT) was 1.8 (95% CI:1.2–2.8) and 2.3
(95% CI:1.3–3.8) for homozygotes (TT) compared to
wildtype (CC) individuals. In a recently published inves-
tigation, Raaschou-Nielsen et al. [66] found in general a
protective effect of the T-allele, which seems to be stronger
in those being diagnosed in the age of 50–60 years (ORTT
vs. CC = 0.35, 95% CI: 0.2–0.8) than in older patients (ORTT
vs. CC = 0.8, 95% CI: 0.4–1.6). However, within those
smoking more than 20 g tobacco a day the T-allele was
found to carry a risk for lung cancer (ORCT vs. CC = 1.95*,
95% CI: 1.4–2.6; ORTT vs. CC = 1.7*, 95% CI: 1.1–2.7; *per
5 g tobacco a day). Hence, the T-allele increases the risk
for lung cancer in smokers. Yang et al. [60] reported for
never smokers a non-significant decreased risk for CC-car-
riers in younger (<50 years, OR = 0.6, 95% CI: 0.3–1.2)
and an even stronger and significant decreased risk in
older (>80 years, OR = 0.12, 95% CI: 0.02–0.7) patients.
However, in older smokers the risk for lung cancer was
increased for CC-carriers (OR = 3.3, 95% CI: 1.3–8.4),
which is contradictory to the findings of Ratnasinghe et al.
and Raaschou-Nielsen et al. The T-allele acts protective
against lung cancer in smokers.
While the distributions of genotypes of all mentioned
investigations are rather similar within controls, the pro-
portion of the CC-wildtype is much smaller in the case-
sample of Ratnasinghe et al. (29%) than in any other case-
sample (45% to 61%). With the investigation of Yang et
al. [60] we share the focus on early-onset patients. Esti-
mates for OR in younger smokers are not reported by
them, but the crude odds ratios of the younger study sam-
ple (age <50 years, calculated from table III in Yang et al.
[60]) are ORCT vs. CC = 0.7 and ORTT vs. CC = 0.6 and within
the confidence intervals of our estimations (Table 4).
Yang et al. constructed hierarchical trees of risk modifying
factors performing recursive partitioning (RPART). By this
procedure, the sample size of effects in lower hierarchical
steps becomes fairly small. They included in their final
conclusion a non-significant effect of GPX1(Pro200Leu)
within never-smokers, but didn't show any effect by
GPX1(Pro200Leu) within smokers. In contrast to them we
could see significant association by GPX1(Pro200Leu) for
heavy SEL, as for current and former smokers, with ORs
from 0.3 to 0.5. We missed significance for never and light
and for moderate smokers possibly owing to low sample
size. Nevertheless, the estimated effect was of the same
size. Hence, T-carriers seem to have some genetic protec-
tion against lung cancer within smokers of age 50 years or
less. Sensitivity analysis could demonstrate that even
under worst conditions for missing genotypes the findings
were qualitatively identical and genotyping errors
appeared as missing at random. Finally, findings from our
sample of early-onset cases are consistent with the previ-
ous reports, when restricting samples to age of 50 years or
less [60]. However they are in conflict with findings from
non-early-onset samples [63,66].
Several factors have yet been identified to modify the
activity of GPX. The consumption of fruits and vegetables
as well as a supplementation with the trace elements sele-
nium in populations with a low rate of daily intake affect
the activity of GPX in human erythrocytes [67]. Serum
concentrations of selenium and erythrocyte GPx activity
were lower in smokers [68]. Additionally it was reported
that alcohol induces lipid peroxidation which might lead
to a decrease in GPX activity. Ravn-Haren and colleges
could recognize a correlation between alcohol consump-
tion and GPX activity to be modified by the
GPX(Pro200Leu) genotype [63,69]. Stronger association
between smoking, alcohol intake and lung cancer was
seen in carriers of the genotype TT of GPX1(Pro200Leu)
than in carriers of genotype CC [11].
Thus the observed association between GPX(Pro200Leu)
and the risk for lung cancer might be caused by the com-
plex interplay between smoking, nutrition and GPX activ-
ity.
EPHX1
Microsomal epoxide hydrolase (EPHX1) has a putative
dual function for enzyme activity which possibly modifies
lung cancer risk. On the one hand EPHX1 catalyzes the
hydrolysis of epoxides to less reactive substances easier to
be solubilised. On the other hand it activates some acr-
ylamine metabolites or polycyclic aromatic hydrocarbons
of cigarette smoke into a more carcinogenic form [57]. It
is also reported that endotoxin in organic dust induces
lung function decline. The strength of such a longitudinal
decline is modified by the investigated EPHX1 polymor-
phism [70].
The activation or inactivation effects of EPHX1 may
depend on the specific compounds being metabolized.
Changing the structure of the enzyme via polymorphisms
in EPHX might have both, protective or promotional
effect on developing of lung cancer in smokers. There are
two mainly discussed variants of the EPHX gene, one in
exon 3 and the other in exon 4. In exon 3 a C has been
substituted for a T, resulting in an amino acid exchange at
codon 113 (Tyr113His). This amino acid exchange resultsPage 9 of 12
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exon 4 a C to A transition causes a histidine to arginine
change at codon 139 (His139Arg) with an in vitro increas-
ing enzyme activity (25%) [71].
Two meta-analyses have been recently published investi-
gating the genetic impact of EPHX1(His113Tyr) (T→C
polymorphism in exon 3) without age constraints and did
not find an association with lung cancer (OR = 0.96, 12
studies included [46] and OR = 0.98, 7 studies included
[72]). However, Lee et al. [72] reported a significant
decrease in lung cancer risk after adjustment for age, sex,
smoking and study centre in pooling data of four pub-
lished and four unpublished case-control studies (OR =
0.7, 95% CI: 0.51–0.96), which is confirmed for a white
population in a recently published meta-analysis (5 stud-
ies combined, OR = 0.65, 95% CI: 0.44–0.96) [73]. The
authors of the first meta-analyses suggested a possible
protection for heavy smokers carrying the CC genotype
which is in line with our results in young high tar exposed
lung cancer patients (OR = 0.8, 94% CI: 0.3–1.9). How-
ever, the risk reduction at a moderate level of smoking
exposure in our study was estimated even stronger by a
point estimate of OR = 0.2, lower than the confidence
interval given by Lee et al. [60].
GPX1(Pro200Leu) and EPHX1(His113Tyr)
In combining both observed protective alleles of both
genes we defined gPS, a genetic protection score. We could
observe a positive association between the count of pro-
tective alleles and the reduction of tobacco smoke
induced risk for lung cancer (OR = 0.20, 95% CI: 0.07–
0.60).
Within our control group 53% are T-carriers for the
GPX1(Pro200Leu) variant and 50% are C-carriers for the
EPHX1 variant. Therefore, we might expect 3 out of 4 indi-
viduals of the population to have some genetic protection
against lung cancer at younger age. However, the risk rais-
ing effect of smoking cigarettes is much stronger. Even
under double protection by GPX1(Pro200Leu) and
EPHX1(His113Tyr) the risk of current smokers is at least
4.5-times larger than in unprotected never and light
smokers.
In conclusion, our study investigates the association of
several candidate genes with lung cancer in the young.
Only some of the results from this sample of early-onset
lung cancer patients are consistent with previously
reported age independent findings or suspicions. How-
ever, their role in the developing process is different.
Some remarks to the study design
We used a candidate gene approach based on the litera-
ture lung cancer as a whole. Thus, we can identify no other
than previously reported susceptible genes to general age
of onset within our young age sample. We also restricted
considerations to the most promising marker per gene
and did not consider haplotypes within candidate genes.
So far, results presented here need to be understood as fur-
ther investigation of controversial findings. We limited
the chance of false positive results by applying a two-step
strategy. First we performed two-group-comparisons with
BWS-tests, followed by multiple logistic regression mode-
ling for selected markers only.
For four markers the call rate of genotyping is shortly
lower than 90%, which results from some suboptimal
logistic in the early phase of the study and is not due to
genotyping errors.
Conclusion
Smoking is the most important risk factor for young lung
cancer patients. However, this study provides some sup-
port for the T-Allel of GPX1(Pro200Leu) and the C-Allele
of EPHX1(His113Tyr) to play a protective role in early
onset lung cancer susceptibility.
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